These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 30626961)
21. Drug to treat rare pediatric liver disease. FDA Consum; 2002; 36(2):5. PubMed ID: 11989476 [No Abstract] [Full Text] [Related]
22. Nitisinone arrests ochronosis and decreases rate of progression of Alkaptonuria: Evaluation of the effect of nitisinone in the United Kingdom National Alkaptonuria Centre. Ranganath LR; Khedr M; Milan AM; Davison AS; Hughes AT; Usher JL; Taylor S; Loftus N; Daroszewska A; West E; Jones A; Briggs M; Fisher M; McCormick M; Judd S; Vinjamuri S; Griffin R; Psarelli EE; Cox TF; Sireau N; Dillon JP; Devine JM; Hughes G; Harrold J; Barton GJ; Jarvis JC; Gallagher JA Mol Genet Metab; 2018 Sep; 125(1-2):127-134. PubMed ID: 30055994 [TBL] [Abstract][Full Text] [Related]
23. Alkaptonuria - Past, present and future. Davison AS; Norman BP Adv Clin Chem; 2023; 114():47-81. PubMed ID: 37268334 [TBL] [Abstract][Full Text] [Related]
24. From the Food and Drug Administration. Schwetz BA JAMA; 2002 Mar; 287(9):1103. PubMed ID: 11879090 [No Abstract] [Full Text] [Related]
25. Determinants of tyrosinaemia during nitisinone therapy in alkaptonuria. Ranganath LR; Milan AM; Hughes AT; Davison AS; M K; Norman BP; Bou-Gharios G; Gallagher JA; Imrich R; Arnoux JB; Rudebeck M; Olsson B Sci Rep; 2022 Sep; 12(1):16083. PubMed ID: 36167967 [TBL] [Abstract][Full Text] [Related]
35. Osteoarticular cells tolerate short-term exposure to nitisinone-implications in alkaptonuria. Mistry JB; Jackson DJ; Bukhari M; Taylor AM Clin Rheumatol; 2016 Feb; 35(2):513-6. PubMed ID: 26024586 [TBL] [Abstract][Full Text] [Related]
36. [Pharmacological and clinical profile of nitisinone (Orfadin(®) Capsules): a therapeutic agent for hereditary tyrosinemia type 1]. Minoura H; Iwai M; Taniuchi Y; Katashima M; Takahashi H Nihon Yakurigaku Zasshi; 2015 Dec; 146(6):342-8. PubMed ID: 26657126 [No Abstract] [Full Text] [Related]
37. Acute fatal metabolic complications in alkaptonuria. Davison AS; Milan AM; Gallagher JA; Ranganath LR J Inherit Metab Dis; 2016 Mar; 39(2):203-10. PubMed ID: 26596578 [TBL] [Abstract][Full Text] [Related]
38. NTBC and Correction of Renal Dysfunction. Maiorana A; Dionisi-Vici C Adv Exp Med Biol; 2017; 959():93-100. PubMed ID: 28755187 [TBL] [Abstract][Full Text] [Related]
39. Health care policy. Reforming off-label promotion to enhance orphan disease treatment. Liang BA; Mackey T Science; 2010 Jan; 327(5963):273-4. PubMed ID: 20075234 [No Abstract] [Full Text] [Related]
40. Neuropsychological outcome of NTBC-treated patients with tyrosinaemia type 1. De Laet C; Munoz VT; Jaeken J; François B; Carton D; Sokal EM; Dan B; Goyens PJ Dev Med Child Neurol; 2011 Oct; 53(10):962-4. PubMed ID: 21745202 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]